In Japan, there are 40 million people with hypertension, 30 million with hypercholesterolemia, and 23 million with diabetes, including the reserve group. Looking at these figures alone, it seems that Japan has a huge number of sick people. But I think of this situation as accepting the tricks of pharmaceutical companies and doctors to sell drugs,



For example, the diagnostic criteria for high blood pressure that it is better to treat from this level continues to be lowered without any specific evidence. The standard of systolic blood pressure (systolic), which was 160mmhg for a long time, was 140mmhg in 2000, and has dropped to 130mmhg in the metabolic syndrome screening in 2008.



As you age, your blood pressure usually rises. Above the age of 50, a systolic blood pressure of 130 mmHg is normal. However, according to the current standards, even with this level, a patient with high blood pressure would be treated with antihypertensive drugs.



As a result, the pharmaceutical industry has benefited greatly. Sales of antihypertensive drugs, which were about 200 billion yen in 1988, exceeded 1 trillion yen in 2008. Sales have increased sixfold in 20 years. It can be said that this is a great success for blood pressure surgery.



The same goes for total cholesterol levels. It was already revealed 10 years ago that people with high ratings live a long time, but the standard has hardly been raised. The amount of statin-based cholesterol-lowering drugs is sold at 260 billion yen annually. Cholesterol-related medical expenses are said to be three times that amount. The problem is that lowering blood pressure or cholesterol with drugs increases the risk of shortening life even if levels improve. This is a fact that has been revealed as a famous painting through a worldwide follow-up of tens of thousands of people. (Same source as below, Makoto Kondo)

작성

Cure of Diabetes

mi jung park
2022-01-18
조회수 1132198

In case of type 1 diabetes, insulin treatment is required. In the case of type 2 diabetes, lifestyle modification is the basis, and additional drug administration may be required. In the case of oral medicine, it is taken 1 to 3 times a day, and depending on the time of action of the medicine, the time taken and side effects are slightly different.


Oral hypoglycemic agents are largely divided into insulin secretagogues and insulin sensitivity improvers. Insulin secretagogues include sulfonylurea and meglitinide. Sulfonureas, a commonly prescribed drug, can cause hypoglycemic conditions. These include amaryl (ingredient: glimepiride), diamicron (ingredient: gliclazide), and daonyl (ingredient: glibenclamide).


Meglitinide, a type of insulin secretagogue, is a very fast-acting agent that is taken before meals. nide mitiglinide) and the like.


Insulin sensitivity improving agents are characterized by almost no hypoglycemia when taken alone, and include metformin, a biguanide-based drug, and Avandia (ingredient: rosiglitazone), a thiazolidinedione-based drug, and Actos ( Ingredient name: pioglitazone), etc. In addition, there are glucobai (ingredient name: acarbose) and Basin (ingredient name: voglibose) that delay carbohydrate absorption in the small intestine.


Meanwhile, there is a GLP-1 agonist developed using the action of GLP-1 (glucagon-like peptide-1; glucagon-like peptide-1), a hormone that lowers blood sugar, and exenatide and This includes injections such as liraglutide. In addition, a DPP-4 inhibitor that inhibits the action of DPP-4 (dipeptidyl peptidase-4; dipeptidyl peptidase-4), an enzyme that rapidly inactivates GLP-1, is also used, and Januvia (ingredient name: Sitagl) There are liptin sitagliptin), gabs (ingredient name: vildagliptin), and saxagliptin.


Recently developed new drugs include SGLT2 inhibitors that inhibit glucose reabsorption in the kidneys, and these are known to have an effect on preventing cardiovascular complications, but long-term side effects require follow-up.


Insulin is currently available as an injection, and in principle, it is administered by subcutaneous injection, and the method of administration differs depending on the time of action. It has a faster blood sugar lowering effect than oral medicines, can be used safely even in environments where oral medicines cannot be used, and has no dose limit, but disadvantages include rejection of needles and difficulty in administration.


Insulin is classified into super fast-acting, short-acting, intermediate-acting, and long-acting insulin depending on the duration of action. The detailed description is as follows.

Rapid-acting insulin begins to take effect within 15 minutes after administration, and the effect usually lasts 3 to 4 hours. Therefore, it is administered right after or just before a meal, and it is easy to control blood sugar after a meal. These include insulin lispro, insulin aspart, and insulin glulisine.


The fast-acting insulin is the insulin used to control postprandial blood sugar before the super fast-acting insulin was released, and regular insulin belongs to this category. It usually takes effect 30 minutes to 1 hour after administration, and the effect usually lasts 2 to 4 hours.


Intermediate-acting insulin (NPH insulin) has an effect 1 to 3 hours after administration, and the effect usually lasts 12 to 16 hours, and the highest effect is shown at 6 to 8 hours after administration. Insulin is characteristically cloudy.


Long-acting insulin includes insulin glargine, insulin detemir, and degludec, and is mainly used as basal insulin because of its longer action time and constant effect than intermediate-acting insulin. 

0 0